TSS
AKBA icon

Two Sigma Securities’s Akebia Therapeutics AKBA Stock Holding History

Two Sigma Securities’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-40,826
Closed -$77.6K – 1424
2024
Q4 		$77.6K Buy
40,826
+27,517
+207% +$47.8K 0.01% 1137
2024
Q3 		$17.6K Buy
+13,309
New +$17.8K ﹤0.01% 2514
2024
Q2 		– Sell
-32,073
Closed -$58.7K – 2933
2024
Q1 		$58.7K Buy
32,073
+20,202
+170% +$32.3K ﹤0.01% 2549
2023
Q4 		$14.7K Sell
11,871
-5,032
-30% -$5.13K ﹤0.01% 2767
2023
Q3 		$19.3K Sell
16,903
-8,382
-33% -$10.8K ﹤0.01% 2577
2023
Q2 		$23.1K Sell
25,285
-112,752
-82% -$109K ﹤0.01% 2487
2023
Q1 		$77.4K Buy
138,037
+54,269
+65% +$41.5K ﹤0.01% 2231
2022
Q4 		$48.3K Buy
83,768
+57,634
+221% +$18.1K ﹤0.01% 2169
2022
Q3 		$8K Sell
26,134
-9,465
-27% -$3.71K ﹤0.01% 2426
2022
Q2 		$13K Buy
35,599
+3,430
+11% +$1.44K ﹤0.01% 2013
2022
Q1 		$23K Sell
32,169
-742
-2% -$1.59K ﹤0.01% 1958
2021
Q4 		$74K Buy
32,911
+11,550
+54% +$31.5K ﹤0.01% 1213
2021
Q3 		$62K Buy
+21,361
New +$61K ﹤0.01% 1361
2021
Q2 		– Sell
-14,046
Closed -$48K – 1477
2021
Q1 		$48K Buy
+14,046
New +$50.6K ﹤0.01% 737
2020
Q1 		– Sell
-30,694
Closed -$194K – 1310
2019
Q4 		$194K Buy
+30,694
New +$146K ﹤0.01% 2099
2019
Q1 		– Sell
-10,285
Closed -$57K – 1788
2018
Q4 		$57K Buy
+10,285
New +$80.5K ﹤0.01% 1923

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Two Sigma Securities's AKBA Position: Q1 2025 in Review

Two Sigma Securities sold out of Akebia Therapeutics (AKBA) in Q1 2025, closing a stake of 40,826 shares — an estimated $77.6K sold.

Two Sigma Securities first reported a position in AKBA in Q4 2018 and held it in 16 quarters. The position peaked at $194K in Q4 2019. 143 funds tracked by Wall St. Rank hold AKBA as of Q1 2025.

  • Two Sigma Securities reported no remaining Akebia Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Two Sigma Securities sold 40,826 Akebia Therapeutics shares in Q1 2025, an estimated $77.6K.
  • Two Sigma Securities first reported a position in Akebia Therapeutics in Q4 2018 and held it in 16 quarters.
  • Two Sigma Securities's Akebia Therapeutics position peaked at $194K in Q4 2019.
  • 143 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2025.

Based on Two Sigma Securities's 13F filing for Q1 2025, filed 15 May 2025.